Neurogene stops Batten gene therapy after FDA denies request, dealing double dose of bad news Read more →

Incyte's $750M buyout rocked by pause on key trial, asset cull Read more →

Nearing potential FDA approval, BridgeBio shows additional positive data on ATTR-CM candidate acoramidis Read more →